Samsung Biologics Bets 2.7 Trillion Won on Peptides in South Korea’s Largest Biotech M&A Deal
Samsung Biologics is making a major push into peptide-based medicines—widely used in weight-loss and diabetes therapies—through the planned...
Search results for "contract development and manufacturing"
Samsung Biologics Slashes Biopharma Development Timeline to 9.5 Months at BioProcess International 2026
Samsung Biologics has unveiled a process innovation case study demonstrating a reduction in biopharmaceutical development timelines from 13 months...
Samsung Biologics to Raise ₩3 Trillion in Rights Offering to Fund ₩2.7 Trillion Acquisition of PolyPeptide Group
Samsung Biologics is proceeding with a 3 trillion won ($2.25 billion) rights offering, directing approximately 90% of...
Global Asset Managers Expand Holdings in South Korean Pharma and Biotech
Major institutional asset managers are steadily increasing their equity stakes in South Korean pharmaceutical and...
South Korea Ranks in GSK’s Global Top 10 for Clinical Research, with Over 70 Trials Underway
"South Korea is among the top 10 markets in GSK’s global clinical research. More than 70 clinical programs are...
Samsung Biologics Posts 586.4 Billion Won Q2 Profit, But Labor Uncertainty Looms
Samsung Biologics reported second-quarter revenue in the 1.3 trillion won range this year, a 30% increase from the same...
Hanmi Pharm Revives 'LAPSCOVERY' Momentum with $1.26B Eli Lilly Licensing Deal
Hanmi Pharmaceutical has licensed its novel drug candidate sonefpeglutide to global pharmaceutical giant Eli Lilly and...
Eli Lilly to Acquire GC Biopharma’s Curevo Vaccine in Blockbuster $1.5 Billion Deal
GC Biopharma’s U.S. affiliate, Curevo Vaccine, is set to be acquired by global pharmaceutical giant Eli Lilly in a deal...
Daewoong Pharmaceutical to Distribute 'The Spirokit' Digital Pulmonary Function Tester
As pulmonary function testing is officially integrated into standard general health checkups this year, Daewoong...
SK Bioscience Secures First EU-Led Vaccine Project in Landmark Triple Consortium
SK Bioscience announced on February 26th that a tripartite consortium including the company has been selected for the...